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Glutathione—the simple tripeptide composed of glutamic acid, cysteine, and glycine—is
customarily defined as “the most important intracellular non-enzymatic antioxidant,” and most
of the time such a swift definition is deemed sufficient to epitomize its functions in cellular
homeostasis. But glutathione in fact is much more than that, as decades of passionate, unceasing
research have documented. Just for instance, extracellular glutathione has also been shown to
be of paramount importance in selected conditions—notably, respiratory pathophysiology—and
functions of GSH other than antioxidant (indeed, even prooxidant) have been identified in years.
The title of the present e-Book explicitly recalls that of a fortunate commentary we wrote several
years ago, back in 2003 (Pompella et al., 2003). During the decade or so since then, the interest in
glutathione and related enzymes has continued to raise—slightly but steadily, as it had done in the
decade preceding that publication (Figure 1). As also documented by the articles collected here,
GSH biochemistry and pharmacology in fact involve wide and varied fields of interest in biology
and medicine—from protein taxonomy to plant physiology, epigenetic regulation, cell energetics
and the apoptosis/survival balance, carcinogenesis, drug resistance of cancer cells, inflammation-
based diseases etc. It is thus very likely that experimental studies of diverse nature end up by
encountering GSH at some earlier or later stage.
The present collection of papers can be a useful tool in order to feel the pulse of current
glutathione research in several fields of biological and medical interest. To start with, the first two
articles in the series both offer—from distinct points of view—intriguing conceptual re-evaluations
of GSH biochemical significance. First of all, the Opinion paper by Prof. L. Flohé’s group provides
punctual considerations pointing out that the electrochemical potential of GSH cannot entirely
describe its redox regulating functions, and other kinetics and thermodynamic factors may be
needed for a more comprehensive appraisal. Enzyme catalysis should be regarded as prioritary
vs. thermodynamic or electrochemical parameters in GSH-dependent redox events; in short—the
way these authors put it—“redox regulation by GSH needs enzymes” (Berndt et al., 2014). On the
other hand, the article which follows is an admirably straightforward and clear Original research
paper. Basing on the results of simple in vitro experiments with hypochlorous acid (HOCl), Profs.
Haenen and Bast conclude that the partially oxidized forms of GSH generated in the GSH-HOCl
reaction also are effective antioxidants, and do substantially contribute to the overall scavenging
activity. Therefore the latter is best measured by the total number of reactive molecules scavenged,
rather than by the reaction rate of the GSH-HOCl reaction (Haenen and Bast, 2014).
The two subsequent articles deal with structural and evolutionary aspects. The first one,
an Original research paper, is an intriguing exploration of the factors which may have
contributed to the selection of redox-active disulfides during the evolution of protein structures.
S-glutathionylation, and the action of glutaredoxin as well as thioredoxin, are among these
factors. The authors select three proteins for detailed analysis—CD4, ERO1, and AKT—and with
the help of phylogenetic trees propose how redox-active disulfides may appear into a protein
structure during evolution, by stepwise mutation of two residues in the native sequence to cysteine
(Mohanasundaram et al., 2015). The following Review article by Lallement et al. is also focused
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FIGURE 1 | No. of scientific papers published in the period 1992–2014 and quoting “glutathione” as title word. Source: Entrez PubMed, http://www.ncbi.
nlm.nih.gov/pubmed?cmd=Search.
on evolutionary aspects, and in particular on cysteine-containing
glutathione transferases (Cys-GSTs) of plants. These peculiar
enzymes can effect protein de-glutathionylation, thus mimicking
the action of glutaredoxin; but, apart from the obvious function
of dehydroascorbate reductases in regeneration of ascorbic acid,
the functions of other Cys-GSTs in plants remain obscure. The
authors try here to shed some light, and indeed do a precious
job by including a phylogenetic analysis of the 14 classes of
plant GSTs and a comprehensive survey of all aspects involved:
gene expression, structure, catalytic mechanisms, subcellular
localization, potential physiological roles (Lallement et al., 2014).
Epigenetics is the subject of the following two papers. The
Opinion article by Garcia-Giménez and Pallardò highlights the
roles played by GSH in gene regulation, as it directly binds to
cysteine residues in H3 histone and it regulates the activity of
S-adenosyl methionine synthetase (MAT1A), a major enzyme
involved in DNA methylation. The authors thus propose that
GSH is a factor linking epigenetic regulation with the redox
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status of the cell (García-Giménez and Pallardó, 2014). The
subsequent Review is focused instead on the epigenetic regulation
of glutathione S-transferase P1 (GSTP1), an ezyme activity also
provided with “caretaker” function. Inactivation of this gene is
often observed in human neoplasia (prostate, breast, and liver
cancer, as well as leukemias), and is the result of acquired somatic
CpG island promoter hypermethylation. The authors underscore
the possibility of using such GSTP1 epigenetic alterations as
biomarkers for early diagnosis (of prostate cancer in the first
place), as well as potential targets of preventive or therapeutic
treatments (Schnekenburger et al., 2014).
GSH of mitochondria plays a defensive role against reactive
oxygen species deriving from respiration, and regulation of
its levels impacts on the permeabilization of mitochondrial
membrane, i.e., the first step in several instances of programmed
cell death. This is the subject of the subsequent two Reviews and
one Opinion article. The first paper (Ribas et al., 2014) includes
a comprehensive appraisal of the involvement of mitochondrial
GSH alterations in several important human pathologies, as
well as a survey of the available strategies capable of restoring
the mitochondrial pool of GSH and/or other antioxidants. The
second Review evaluates the involvement of S-glutathionylation
and/or thiols redox modulation in cell signaling related to nitric
oxide induced responses, autophagic pathways and viral infection
(Aquilano et al., 2014), while the Opinion paper which follows is
an interesting reappraisal of studies showing how apoptosis can
be linked to an intracellular oxidant stress consequent to active
GSH extrusion, leading to formation of inter-protein disulfides
implicated in the proapoptotic signaling. The authors note that
GSH depletionmay promote either pro-apoptotic or pro-survival
pathways, depending on its kinetics of depletion, and speculate
that the reactive cysteines of proteins involved in the opposite
responses (e.g., cell-protective NF-kB component p50 vs. pro-
apoptotic Bax) may be differently modulated according to the
swiftness of the redox imbalance (De Nicola and Ghibelli, 2014).
The two subsequent Original research papers are dedicated
to inflammation and immune-related diseases. The first one
reports data confirming that erythrocytes of HIV patients show
decreased GSH levels, an effect known to be due to HIV-1
transactivator protein (TAT) altering the expression of GSH
biosynthetic enzymes (Choi et al., 2000). The authors conclude
that resupplementing intracellular GSH by means of liposomal
formulations may be effective in restoring immune functions,
such as e.g., the antimycobacterial activity in macrophages
from HIV patients (Morris et al., 2014). The other Original
research paper in this subsection is concerned with an aspect
of high relevance in respiratory medicine, i.e., the fundamental
antioxidant and antiinflammatory role played by GSH contained
in the epithelial lining fluid of airways. These levels are subject
to the catabolizing activity of gamma-glutamyltransferase (GGT),
an enzyme increasing in airways during inflammation. The
authors elegantly demonstrate—in the IL-13 model of allergic
airways inflammation in the mouse—that the pharmacological
inhibition of airways GGT by means of a synthetic substrate
analog, GGsTop (Han et al., 2007) results in a remarkable sparing
of extracellular GSH, and can therefore augment antioxidant
defenses and protect lung parenchyma against the prooxidant
insults deriving from accumulation of activated inflammatory
cells (Tuzova et al., 2014). The described approach might prove
indeed valuable in lung diseases that perturb the extracellular
lining fluid GSH pool, such as cystic fibrosis, acute respiratory
distress syndrome (ARDS) and chronic obstructive pulmonary
disease.
The conclusive three papers in our e-Book deal with cancer-
related issues. The Review article by Prof. S. Toyokuni is a
survey of the factors affecting the complex interplay of cellular
transport systems for iron with those in charge of cellular
supply of cysteines (Toyokuni, 2014). Excess iron is strictly
linked with promotion of carcinogenesis, and on the other
hand, the expression of the cystine/glutamate antiporter is
intimately associated with ferroptosis, an iron-dependent, non-
apoptotic form of cell death observed in cancer cells. The role
of Nrf2/Keap1 signaling pathway—one of the most important
cell defense and survival pathways—is discussed, as well as the
recent finding that cancer stem cells in certain neoplasias present
a stabilization of the xCT subunit of the x–c cystine/glutamate
antiporter, leading to increased intracellular GSH levels. Thismay
explain the robustness of cancer cell defenses against oxidative
stress, and is likely implicated in resistance to chemotherapeutic
agents (Ishimoto et al., 2011).
The paper which follows also is a Review article, and focuses
on the expression of glutathione S-transferases (GSTs) as well as
of GGT as factors in the promotion of a more aggressive and
resistant phenotype of cancer cells. GGT activity allows cells to
maintain/reconstitute their GSH supplies which are utilized by
GSTs for conjugation of xenobiotics, and in this way both enzyme
activities synergistically contribute to detoxification of anticancer
drugs. Nevertheless, pro-drugs have been synthesized that can
be selectively activated by GSTs and GGT, whose expression
is thus turned into a factor of vulnerability of the cancer cell.
The Review recapitulates the different drug strategies involving
GSH-conjugates and enzymes of the mercapturic acid pathway
employed over the last two decades (Ramsay and Dilda, 2014).
Amongst the long list of compounds investigated, a limited
number of GSH-conjugates have recently progressed toward
clinical trials, including both GST-activated nitrogen mustard
TLK286 and GGT-activated arsenic-based prodrugs GSAO and
Darinaparsin.
The very last paper of the e-Book also is the most speculative
contribution to this series. In their Opinion paper Pennacchio
et al. (2014) start from the observation that selected bacterial
strains (Helicobacter spp. in the first place, plus others) can
secrete active GGT enzyme, which causes depletion of GSH
in cells of infected epithelia. The resulting oxidant stress has
been put in connection with the invading ability of bacteria,
i.e., with their virulence (Gong et al., 2010). A very similar
phenomenon has been observed with selected parasitic insects,
capable to secrete a GGT-containing venom capable of inducing
GSH depletion in tissues of parasitized organisms. The authors
highlight that several human neoplastic cell lines have also been
shown to secrete active GGT enzyme, in the form of exosome-like
vescicles (Franzini et al., 2009) resembling those secreted by
Helicobacter (Zhang et al., 2013). It is thus proposed that the
phenomenon may represent a true evolutionarily convergent
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strategy, spanning across very diverse life forms, aiming at
depleting GSH levels in order to impair host’s redox regulation
and defenses to facilitate invasion and colonization. In this
perspective cancer cells could be regarded as just another species
of invasive “microrganisms,” and such a view appears consistent
with other recent, unrelated observations pointing at the fact that
cancer might conceivably be treated like an infectious disease,
by even repurposing approved antibiotics for anticarcer therapy,
across multiple tumor types (Lamb et al., 2015).
In summary, the articles collected in the present e-Book
represent an assortment of updated data, hypotheses and
interpretations deriving from a pretty wide spectrum of precincts
in current biomedical research. This was somewhat expected, due
to the exquisite interdisciplinarity of the subject, and in some way
even desired, to fully exploit the informative potential typically
owned by an online publication. Rather, as a matter of fact, it is
felt that soon enough there might again be the need of a Topic
and e-Book on glutathione—this seemingly inexhaustible cellular
protagonist.
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